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ABSTRACT 
Nonsteroidal anti-inflammatory drugs (NSAIDs) may delay bone healing. The purpose of 
this prospective controlled study was to investigate whether ibuprofen affects bone 
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mineral density, turnover biomarkers, and histomorphometric characteristics of the callus 
after a Colles’ fracture.  
This study was a single centre, triple-blinded, randomised clinical trial. Ninety-five 
patients (eighty females) with displaced Colles’ fracture, median age 65 (range 40–85) 
years were included in the study and operated on by external fixation from June 2012 
through to June 2015. 89 patients received interventional medicine and 83 completed the 
one-year follow-up. The 7-days ibuprofen group received 600 mg of ibuprofen three 
times a day (N=29), the 3-days ibuprofen group received ibuprofen for three days (N=30) 
and a placebo for the following four days, and finally, the placebo group received a 
placebo for seven days (N=30). The primary outcome was the difference in bone mineral 
density between the ultra-distal region of the injured and non-injured radius at three 
months after surgery. The histomorphometric outcomes included assessment of callus 
tissue volume- and surface fractions at six weeks postoperatively. The biomarkers 
Osteocalcin and CrossLaps were measured at baseline, one week, two weeks, six weeks, 
three months, and one year. We included the results of the dropped-out patients in the 
intention to treat analysis. There was no difference between treatment groups in bone 
mineral density, histomorphometric estimations and changes in bone biomarkers. These 
findings may offer an indication of ibuprofen as a bone-safe analgesic treatment in the 
acute fracture phase. 
KEYWORDS: ibuprofen, fracture, DXA scanning, bone biomarkers, callus 
histomorphometry. 
INTRODUCTION 
The distal forearm fracture is a common injury in the elderly population. Nonsteroidal 
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anti-inflammatory drugs (NSAIDs) are one of the most used analgesics. There is still no 
consensus as to whether short-term NSAID treatment affects bone healing.1,2 Despite 
this, it is a general recommendation to use caution when treating pain with NSAIDs for 
fracture patients, 2 and further prospective clinical studies are warranted.3 
More than 1.46 million new cases of Colles’ fractures were reported in 1998 in the 
United States, accounting for 1.5% of all emergency department cases.4 Many older 
patients sustain this fracture and may subsequently experience the reduced function of 
the injured wrist, especially if there is secondary dislocation of the bone fragments.5 
Inflammation is an essential part of the early stage of bone fracture healing.6 Mechanical 
damage to the bone cell membranes releases arachidonic acid, which is converted by 
cyclooxygenase-2 into pain-mediating pro-inflammatory prostaglandins. Fracture 
haematoma, occurring immediately after injury due to broken vessels, is characterised by 
hypoxia and low pH and contains pro-inflammatory cytokines and cells.6 
Cyclooxygenase-2 (COX-2) levels are increased in fracture haematomas and, besides 
having pro-inflammatory activity, are also able to promote angiogenesis and the 
differentiation of mesenchymal cells into osteoblasts.7 
Many animal studies show that NSAIDs have an apparent tendency to delay bone healing 
8, although the healing delay was not noticeable when NSAIDs were used for a short 
period of seven days.9 The prospective human studies report clinical outcomes such as 
dental pocket depth 10, pain, joint motion, and implant migration 11 with no adverse 
effects of NSAIDs reported. 
The randomized, controlled clinical trial, investigating clinical outcomes of Colles’ 
fracture found no influence of ibuprofen on fragment migration, and wrist function.12 In 
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addition to clinical outcomes, described in our previous study, ”DXA, histo, and sero” 
exist in helping to understand the physiological aspects of fracture healing. 
A dual-energy X-ray absorptiometry (DXA scanning) is a non-invasive method for 
determining bone mineral density (BMD) and is widely used in diagnosis of 
osteoporosis. Evaluation of traditional radiographs of healing fractures is highly 
subjective and can have as much as 20–25% inter-physician variability.13 DXA scanning 
allows quantified evaluation of the mineralisation process in the maturing callus. 
Although this method is not the standard tool in orthopaedic surgery, it wins more 
popularity in experimental studies. A high correlation between BMD and mechanical 
rigidity of the callus has been previously reported.14 This method was used for the 
evaluation of the NSAID effect on fracture healing in animal models,15 and has the 
potential for a more accurate fracture repair assessment in humans.13 
Quantitative analysis of bone callus (histomorphometry) is a potential tool for 
investigating bone repair.16 It provides counting and quantification of qualitatively 
assessed bone structures, as bone (lamellar and woven) volume, fibrous tissue, osteoid 
volume, compared with total tissue volume. It also allows evaluation of bone resorption, 
regeneration, and repair process by estimation of bone surface fractions.17 Bone surface, 
covered by osteoid, and/or osteoblasts, represents bone regeneration. On the contrary, 
surfaces, covered by osteoclasts, are the sign of bone destruction/resorption in the 
process of fracture healing.18 
Serological bone biomarkers are another tool with the potential to detect any disturbances 
in the physiology of bone healing. The bony destruction is followed by synthesis of the 
new bone matrix.19 Type I collagen accounts for more than 90% of the organic matrix of 
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bone and is synthesised primarily in bone.20 C-terminal telopeptide (CrossLaps) is 
released after bony breakdown 21, and small peptide fragments are secreted into the 
bloodstream, to be eliminated later by renal excretion. These fragments can be measured 
using immunoassays. During the later fracture healing process, the increased activity of 
osteoblasts can be quantified by measuring serum levels of osteocalcin, the product of 
osteoblasts 22, and thus monitoring the process of bone formation.23 In consideration of 
the non-invasive, dynamic picture of the healing process of the fracture 24, bone markers 
are used for investigative purposes. Their serum levels may vary highly between 
individuals, fracture severity, performed surgery 25, and circadian variation.21 
The research objective is, whether short-term treatment with Ibuprofen in the acute phase 
of Colles’ fracture hampers bone healing and callus maturation in terms of densitometric, 
histomorphometric, and biochemical outcomes in elderly patients. 
MATERIALS AND METHODS 
Study Design and Consent 
Our study was a one-centre, randomised, triple-blinded, clinical trial in which patients 
with unstable Colles’ fracture were recruited for treatment with ibuprofen or placebo 
(Level 1 of Evidence). The study complied with the principles of the Declaration of 
Helsinki 26, followed Good Clinical Practice requirements 27, and was approved by the 
Danish National Medicines Agency (Reg. No. 1253599), the Danish Regional Ethics 
Committee (Reg. No. N-20100015), and the Danish Data Protection Agency (J. no. 
2008-58-155 0028). The study was registered with the European Clinical Trials Database 
(EudraCT number 2010-018543-34) and on the clinicaltrials.gov database 
(NCT01567072). The first author takes responsibility for the integrity and accuracy of 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
the reported data and the fidelity of the study to the protocol. We followed the guidelines 
for reporting parallel group, randomised, controlled trials.28 Independent monitors 
assessed the overall performance of the study. 
Patients Patients with acute, unstable (Older classification type III–IV) Colles’ fractures, 
requiring surgical treatment, were selected at the Aalborg University Hospital, Denmark. 
Another inclusion criterion was to be aged between 40 and 85 years. Exclusions’ criteria 
was age <40 years or >85 years, systematic treatment with NSAIDs, previous fractures of 
the wrist in question, a lack of mental and physical capacity to follow the study 
instructions, medical contraindications to the use of NSAIDs, pregnancy, and 
postoperative displacement of the fracture, if re-operation was indicated. 
Description of Study Treatments 
The study was a prospective, randomised, 1:1:1 controlled, triple-blinded clinical trial 
and consisted of three treatment groups. The 7-days ibuprofen group was treated with 
600 mg of ibuprofen three times daily for seven days. The 3-days ibuprofen group was 
treated with 600 mg of ibuprofen three times daily for the first three days and then given 
a placebo three times daily for the remaining four days. The placebo group was treated 
with a placebo three times daily for seven days. The patients did not receive prophylactic 
medication with proton pump inhibitors or other acid neutralising agents. 
The Hospital Pharmaceutical Department performed block randomisation of 5×9 + 8×6 + 
1×3.  The patient, the surgeon, the data manager, and the statistician were all blinded.   
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Participants received a package of dosed analgesics, each of which included 1 g of 
paracetamol, four times a day for seven days, six 50 mg tablets of tramadol for use at the 
patient’s request, and the specified doses of ibuprofen or placebo. 
We preferred a bridging external fixation using 1.4mm K-wires and a Hoffman II 
external fixator (Stryker®) as the standard method of surgery for all patients in this 
study. 
This operation can be used to treat unstable fractures 29, and remains a viable method of 
treatment.30 The same surgeon performed all surgeries in this study so as to standardise 
the treatment as best as possible. All patients received an infra-clavicular regional nerve 
block, either with or without general anaesthesia.  
For logistical reasons, because of the reduced capacity of the operating department, it 
was not possible to operate on patients at the same time after injury. The median 
operation time was two days post-injury, with an overall range of 1–3 days. 
Outcome Measures 
The primary outcome was the change in BMD in the injured wrist compared with the 
contra-lateral non-injured wrist. Study participants were scanned at three months after 
injury using a Discovery A DXA-scanner (Hologic Inc., MA, USA). For lumbo-sacral 
bone mineral density (LS-BMD) the in vivo precision (CV%) at our facility is 0.90%, for 
total hip 1.00% and for the femoral neck 1.79%. 
The region of interest was determined as the 30 mm wide ultra-distal zone UD, starting at 
the distal ulnar edge of the radius. The outcome was the percentage of injured wrists’ 
BMD compared with the healthy contralateral wrists’ BMD as the reference. 
This article is protected by copyright. All rights reserved. 
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We used the Cobas e 411 ECLIA immunoassay analyser (Roche Diagnostics®) to 
determine our secondary outcome–levels of serum CrossLaps and osteocalcin. To avoid 
circadian level variation, all blood samples were collected from fasting patients at 9.00 
a.m. by a medical laboratory technologist from the Department of Laboratory Medicine. 
We took the blood samples before surgery, at one-week, two-weeks, three-months, and 
one-year follow-up visit for each patient. Blood sampling tubes were filled with a K3-
EDTA and Li-heparin plasma. All blood samples were stored at 5 ºC temperature and 
analysed after the last follow-up visit of the last patient. After two points’ calibration and 
generation of the master-curve, the immunoassay analysis was performed by using 
monoclonal anti-ß-CrossLaps and anti-N-MID osteocalcin antibodies (mouse-derived). 
We took the biopsy from the callus at 6-weeks follow-up visit after surgery at the time of 
external fixation removal in the outpatient clinic. The biopsy location; central dorsal over 
the fracture site, was determined by using an image intensifier and marked on the skin. 
We injected 5 ml of 0.55 Lidocaine for local anaesthesia and used a T-Lok™ Bone 
Marrow Biopsy Needle of 13 G (Product No. DBMNJ1304, ARGON® Medical devices) 
to obtain a 5–7 mm long bone callus biopsy. The material was placed in a plastic tube 
with a 70% alcohol solution and stored at 8 ºC temperature. The biopsies were embedded 
undecalcified in methylmethacrylate (MMA). 7 µm sections were cut using a Jung 
microtome model K (R.Jung GmbH, Heidelberg, Germany), equipped with a tungsten 
knife. The biopsies were cut into the middle in order to get the largest possible area. Four 
levels with three sections on each level were cut with a distance of 175 µm. The sections 
were stained with Goldner Trichrome. 
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We compared histomorphometric characteristics of the volume and surface in the callus 
between treatment groups: bone volume/tissue volume (BV/TV %), woven bone 
volume/tissue volume (WBV/TV %), lamellar bone volume/tissue volume (LBW/TV %), 
fibrous tissue volume/tissue volume (FV/TV %), osteoid volume/tissue volume (OV/TV 
%), osteoid surface/bone surface (OS/BS %), osteoblast surface/bone surface (ObS/BS 
%), and osteoclast surface/bone surface (OcS/BS %).17 
The same observer performed all the analyses using an Olympus BH microscope with 
200 times magnification and polarized light (used for differentiation between lamellar 
and woven bone). All sections of each biopsy were analysed with five sight fields in each 
biopsy. We used a 10 ×10 point ocular-grid was used for volume estimations (with a total 
100 volume points of reference) and ten line-grids for surface estimations (the reference 
was the number of all tissue surface-grid line crossings). The line-grid was rotated 
randomly for each area. Randomly collected biopsies (10%) were evaluated after three 
months to calculate the observers’ repeatability in terms of the coefficient of variation 
(CV%) with 95% of confidence intervals. 
Statistical Analysis, Study size 
The sample size calculation was based on the difference in radius BMD between injured 
and non-injured wrists to test the null hypothesis that NSAID treatment was not inferior 
to the placebo. The calculation was based on a one standard deviation of 4.35% 
difference between the baseline BMD and BMD after injury at three months follow-up 
visit 31 and 3.35% as the non-inferiority limit after 1% error of precision 32 was 
subtracted. The power was defined to 90%. Therefore, to attain a 90% probability of 
rejecting the null hypothesis using a one-sided 0.05 level test, 93 participants (three equal 
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groups of 31 patients) were required. Thus, we recruited 96 participants with 32 patients 
in each treatment group. 
Frequency histograms and Q–Q plots were used to check whether the data from each 
sample were normally distributed or not. In cases where the data were normally 
distributed, and there was homoscedasticity in all samples, the ANOVA test with post 
hoc Tukey test was used to detect significant differences between mean group changes 
for all outcomes. If the data were not normally distributed, the Kruskal–Wallis 
nonparametric significance test was used. 
Additionally, a Z-test was performed to compare the proportions of side effects and 
complications between the treatment groups. 
Intra-observer repeatability of histomorphometric estimations was calculated as the 
coefficient of variance (CV) of all characteristics. We used the formula: CV = �∑(𝑑 𝑚⁄ )
2
2𝑛
, 
where d—the difference between two observations, m—the mean of two observations, 
and n—the number of observations.  
Missing values were multiply inputted and included in statistical analysis. 
 
 
RESULTS 
Study Patients 
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A total of 280 patients were screened between 1 June 2012 and 20 June 2015 (Figure 1, 
Table 1). Of these patients, 95 were included (an enrolment rate of 33.8%), 121 (43%) 
were not asked to participate due to lack of time in the emergency department, 45 (16%) 
were not interested in joining, and 19 (6.8%) fulfilled the exclusion criteria. One pack 
containing study medication was given to a patient with another type of fracture. 
The majority (N=80) of included patients were women, and the median age was 65 years 
(range: 42−85 years). Eighty-nine of the included patients received the allocated 
treatment while the remaining six patients did not (regret, non-compliance). Four patients 
retracted their acceptance to participate, three patients lost their pain diary, one patient 
suffered side effects from the treatment (nausea) and left the study, one patient died 
before the 1-year follow-up, and one patient was operated on in a different way to that 
predefined in this study and was subsequently excluded with a secondary dislocation. 
Two patients were excluded from the histomorphometric evaluation due to insufficient 
quality of the biopsy material. For one patient, DXA scanning was not performed due to 
logistical reasons. Eighty-seven patients, divided into three groups, were analysed 
according to the intention to treat. We also included registered outcomes of the dropped-
out patients in the data analysis. 
 
 
 
DXA Scanning 
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The injured radius demonstrated a higher mean BMD value in the ultra-distal region of 
interest (Figure 2) compared to the non-injured contra-lateral radius. There was no 
significant difference between treatment groups, P=0.69 (Figure 3). 
Histomorphometric Outcomes 
No significant differences between treatment groups in both volume and surface 
estimations (Figure 4) have been detected, 0.38≤P≤0.99 (Table 2). Median intra-observer 
coefficient of variance was 4.7%, range 0-36.9%. There was a trend of less woven bone, 
and more quiet bone (with no formation/remodeling or resorption activities) surface in 
the second evaluation. Bone Biomarkers Our study demonstrated no difference in plasma 
Osteocalcin (0.43≤P≤0.99) and CrossLaps  
(0.37≤P≤0.95) levels at any time in repeated measurements (Figure 5). 
Complications and Adverse Events 
The most common complication was a gastrointestinal disorder, which was observed in 
four patients in the placebo group, seven patients in the 3-days group, and eight patients 
in the 7-days group (Table 3). The number of adverse events in the 7-days ibuprofen and 
placebo groups was significantly different (Z=1.709, P=0.043). We observed no severe 
treatment-related complications in any of the groups. 
DISCUSSION 
Our study has demonstrated no influence of short-term ibuprofen treatment on the 
healing of Colles’ fracture in terms of bone mineral density in the distal radius, 
histomorphometric estimations of the callus, and bone biomarkers.  
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To our knowledge, there is only one study that previously looked at the effects of NSAID 
on BMD of the fractured and non-fractured distal radius, performed by Adolphson et al.33 
This prospective, randomised, double-blinded, and placebo-controlled study showed no 
difference between piroxicam and placebo-treated groups in changes of bone mineral 
content at eight weeks follow-up visit. A direct comparison to our study is difficult as the 
authors looked at the radius just proximal of the fracture. A small sample size, and 
inclusion of severe comminuted Colles’ fractures scheduled for conservative treatment 
and subsequently operated, and excluded from BMD measurement, may influence the 
validity of this trial. 
Van der Poest et al. 31 looked at effect of alendronate on bone mineralisation in the distal 
radius. The baseline DXA scanning in this study was performed approximately three 
months after injury and was 0.40 g/cm2 ± 0.05 in total distal radius at the fracture site. In 
our opinion, it is more reasonable to evaluate only the ultra-distal region of interest to 
assess the quality of fracture healing, as the majority of notable callus fractures occur at 
the distal 38 mm.33 Eastell at al. measured the UD region of the distal radius for 40 
women after Colles’ fracture and found a BMD comparable with our results.34 
Furthermore, this work concluded that with a BMD below 0.4 cm2, the risk of the 
fracture in the distal radius increases significantly. Our study, with the overall BMD in 
the non-injured distal radius of 0.34 ± 0.26 g/cm2 supports this conclusion. 
Bone biomarkers are often used for investigation purposes of osteoporosis and its’ 
treatment. Despite this, some attempts were made to monitor fracture healing by using 
biochemical assays, as fracture healing is associated with increased bone turnover. We 
identified three studies that described changes of Osteocalcin and CrossLaps after the 
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Colles’ fracture. Ingle et al. looked at changes of bone remodeling and resorption 
markers 35 and found a 15% increase of Osteocalcin, consistent with our results. 
CrossLaps increased during the first two weeks also in our study, returning to baseline at 
one years’ follow-up visit. Mallmin et al. enrolled 16 patients with Colles’ fracture and 
found a minor constant increase of osteocalcin of 1 ng/ml during the 16 weeks follow-up 
36, comparable to our results during 3-months follow-up. Wolfl et al. included 30 patients 
with metaphyseal fracture, 14 of them with Colles’ fracture.37 They found CrossLaps 
increased in the bone of the normal BMD group constantly, whereas these levels 
decreased significantly in the bone of the group with low BMD from the first week. 
Direct comparison to our results is difficult because of the short follow-up, and patients 
enrolled received both surgical and conservative treatment. 
This indicates there is still no consensus regarding the use of bone biomarkers for 
fracture healing control. The high variability of plasma levels may suggest plenty of 
confounding factors such as age, the presence of osteoporosis, and metabolic diseases. A 
further investigation is needed to determine the role of remodeling and resorption 
biomarkers in the monitoring of fracture healing.  
Histomorphometric bone analysis is widely used in research of metabolic diseases and 
fracture healing in animal models. 16 There is scant data describing histomorphometric 
characteristics of fracture healing in cancellous bones.18 We presumed that the fracture 
was in the stage of endochondral ossification and formation of new woven bone. By 
affecting bone healing, we expected to detect more fibrous tissue and fewer bone 
fractions, respectively. We presumed to find more resorption and fewer bone formation 
surfaces. No difference in volume and surface fractions was detected after performing 
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eight statistical analysis methods between three treatment groups, thus increasing the 
importance of the histomorphometric part of the study.  
Prolonged treatment with NSAIDs is related to an increased risk of cardiovascular, 
gastrointestinal, and nephrological disorders.38 From a clinical perspective, a lengthy 
treatment is not necessary to relieve pain in the acute period and the following 
osteosynthesis of Colles’ fracture. In our study, no differences in pain experience 
between treatment groups were observed. Treatment with ibuprofen demonstrated a 
sparring effect of escape-tramadol already during the first three days after enrolment, 
P=0.035. 12 
The rate of complications and side effects was significantly higher in the 7-days 
ibuprofen group compared to the placebo group, and gastrointestinal disorders were 
observed in all three treatment groups. A few patients in Placebo group may have 
experienced digestive symptoms due to other factors (e.g., stress during the first days 
after injury or surgery) and this has to be taken into account when determining the 
ibuprofen-related adverse effects. The incidence rates for gastrointestinal disorders in the 
3- and 7-days groups were 23.3% and 27.6%, respectively. These rates were higher than 
in other studies reporting oral treatment with NSAIDs.39 We did not use prophylactic 
medication with proton pump inhibitors or other acid neutralising agents. Given this, the 
number of side effects attributable to the NSAID use may probably be less. 
Our study has several limitations. Patients sustained the fracture at different times of the 
day; some received analgesics on the morning, others on the evening of day one. This 
may lead to some variability when the patient received ibuprofen or placebo treatment 
after the injury. Attempts were made to include all patients during their first visit to the 
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emergency department. It was not possible to assure that all patients received the 
medication at the same time after the injury. 
A few patients also waited a day or more hoping that they only had a sprain or contusion 
and therefore came to the emergency department on the second or third day. Others were 
not asked to participate in the study because the staff were too busy, and this job was left 
to the researcher to do 1–2 days later. These logistical reasons meant that it was not 
possible to assure that ibuprofen was given at the same time point of the fracture 
inflammation phase. The randomization procedure to some extent do compensate for 
these weaknesses. 
The outcomes in our study may be further influenced by many factors such as smoking, 
alcohol consumption, age, and the presence of osteoporosis and its’ treatment. All 
confounding factors, however, were equal distributed among treatment groups. 
The part of the study describing the outcomes had a non-inferiority design. The limitation 
of the non-inferiority design is whether there was a proper sample size. Treatment groups 
demonstrated a difference in the BMD that was less than 25% of the SD within groups 
and differences in bone biomarkers that were less than 10% of the SD within groups. 
With the significance level of 0.05 (according to recommendations for non-inferiority 
trials 40), the sample size in this study was considered to have proper strength. 
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CONCLUSION 
The treatment with ibuprofen did not affect densitometric, histological, and biochemical 
outcomes for Colles’ fracture patients. These findings may offer an indication for 
ibuprofen as a bone-safe analgesic treatment in the acute fracture phase. 
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Figure 2. DXA scanning, regions of interest of distal forearm 
 
Figure 3. BMD outcomes 
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Figure 4. Histologic evaluation of biopsy material in normal and polarized light 
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Figure 5. Dynamics of bone biomarkers in treatment groups 
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Table 1. Baseline characteristics of the study patients 
 
 
 
 
 
 
 Placebo group 3-days ibuprofen 
group 
7-days ibuprofen 
group 
Female\Male 25\5 25\5 24\5 
Average age (years ± 
1SD) 
64.3 ± 4.4 67,8 ± 10 65,4 ± 7.9 
Smokers\Non-smokers 3\27 1\29 3\26 
Osteoporosis treatment 
+\- 
6\24 5\25 7\22 
Dominating\Not 15\15 13\17 14\15 
Total analyzed 30 30 29 
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Table 2. Histomorphometric outcomes 
 
 
 
  
Placebo 
group 3-days ibuprofen group 7-days ibuprofen group P 
BV/TV % 26.6±8 28±8.5 26.3±5.7 0.68 
WBV/TV % 4.4±2.5 6±5.3 4.2±2.3 0.77 
LBW/TV % 18.5±8.5 18.5±7.7 18.5±7.5 0.99 
FV/TV % 50±17.1 46.4±12.2 49±12.3 0.61 
OV/TV % 3.6±1.5 3.4±1.8 3.6±1.6 0.84 
OS/BS % 47.3±14 41.4±16.5 43.7±17.3 0.38 
ObS/BS % 14.8±8.7 11.7±9.9 14.6±11 0.43 
OcS/BS % 9.8±5.6 10.3±5.6 10.4±5.8 0.91 
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Table 3. Adverse events *comparison of the placebo group and the 7-days group 
 
  
Placebo 
group 
3-days 
ibuprofen 
group 
7-days 
ibuprofen group 
Statistics 
Overall 10 of 30 12 of 30 16 of 29 
Z* = 
1.709 P = 
0.043  
Gastrointestinal disorders 4 7 8   
Nerve numbness 6 2 5   
Pinholes infection 0 1 2   
Loosening of osteosynthesis 
material 
0 2 0 
  
Serious secondary 
dislocation 
0 0 1 
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